BRIEF—$195 million DoJ settlement for Sandoz

Novartis’ generics division Sandoz has reached a settlement related to a three-year-long antitrust investigation into the US generic drug industry, concerning misconduct between 2013 and 2015.

Sandoz will pay the US Department of Justice (DoJ) $195 million and will enter into a deferred prosecution agreement (DPA).

The firm is also in settlement negotiations with the DoJ Civil Division to resolve potential related claims and is taking a provision of $185 million for this purpose.